My Portfolio
+
LINK YOUR PORTFOLIO

Taysha Gene Therapies Inc TSHA:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 06/02/26 EDT
5.55quote price arrow down-0.14 (-2.46%)
Volume
1,628,876
52 week range
2.25 - 7.30
Loading...
  • Open5.68
  • Day High5.69
  • Day Low5.43
  • Prev Close5.55
  • 52 Week High7.30
  • 52 Week High Date05/06/26
  • 52 Week Low2.25
  • 52 Week Low Date07/01/25

Latest On Taysha Gene Therapies Inc

Key Stats

  • Market Cap1.595B
  • Shares Out287.36M
  • 10 Day Average Volume2.10M
  • Dividend-
  • Dividend Yield-
  • Beta1.18

Latest On Taysha Gene Therapies Inc

KEY STATS

  • Open5.68
  • Day High5.69
  • Day Low5.43
  • Prev Close5.55
  • 52 Week High7.30
  • 52 Week High Date05/06/26
  • 52 Week Low2.25
  • 52 Week Low Date07/01/25
  • Market Cap1.595B
  • Shares Out287.36M
  • 10 Day Average Volume2.10M
  • Dividend-
  • Dividend Yield-
  • Beta1.18

RATIOS/PROFITABILITY

  • EPS (TTM)-0.38
  • P/E (TTM)-14.74
  • Fwd P/E (NTM)-11.19
  • EBITDA (TTM)-131.382M
  • ROE (TTM)-97.28%
  • Revenue (TTM)7.471M
  • Gross Margin (TTM)-
  • Net Margin (TTM)-1,738.40%
  • Debt To Equity (MRQ)23.23%

EVENTS

  • Earnings Date08/10/2026(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Profile

MORE
Taysha Gene Therapies Inc is a clinical-stage biotechnology company, which is focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. The Company’s lead clinical program, TSHA-102, is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder. The Company is evaluating TSHA-102 in the REVEALPhase I/II adolescent and adult clinical trial, which is a first-in-human...
Sean Nolan
Chairman of the Board, Chief Executive Officer
Sukumar Nagendran M.D.
President, Head of Research and Development, Director
Kamran Alam
Chief Financial Officer
Address
3000 Pegasus Park Drive, Suite 1430
Dallas, TX
75247
United States